Oxford BioMedica PLC (OXBDF)

[marcusl2]

(AAV). These gene therapy vectors do not integrate in the genome of the host cell, thus telomerase only performs its telomere-reparative actions during a few cell divisions before the vector is diluted out.

( surely this is why Lenti for Haemophilia will win out )

hTTps://eurekalert.org/pub_releases/2018-08/cndi-gtv082018.php

0 4 0
Vasant Narasimhan, CEO, Novartis speaking about Kymriah;
Published 4 hours ago August 21, 2018

"Our mindset is for the long run, of a 5 yr journey to get this to a blockbuster enterprise and that’s our general aim. Our aspiration is that this might be a major a part of the Novartis portfolio.

We’re actually Kymriah as a five-year journey. That is a rare drugs and one-of-its-type accepted in kids and offers sufferers who don’t have any different choice of therapy. It’s a science to take the cells out of the physique and reprograming them is actually outstanding however it’s also so new that it’ll take time for the hospitals to be able to take this on and handle such a posh remedy.

From our facet, we have to scale up the operations. Total it’s in keeping with the expectations and we all the time knew that this will likely be a long run technique for cell remedy. The necessary factor is as we go international, and now we have introduced the addition of a producing website in France, we are going to construct the infrastructure that additionally hyperlinks us to all of those hospitals.

We’re specializing in three areas – one is to spend money on manufacturing and make it very environment friendly and scale up, second we’re increasing extra most cancers varieties and we’d consider overlaying all B-cell cancers. My hope as a doctor is to stay in a world the place no affected person ought to die from B-cell most cancers.

We imagine there’s a new science rising that may enable us to create new cell therapies with totally different targets that cell therapies can assault, which we hope can apply to areas like stable tumors and that might presumably be the following breakthrough. Our mindset is for the long run, of a 5 yr journey to get this to a blockbuster enterprise and that’s our general aim. Our aspiration is that this might be a major a part of the Novartis portfolio.

hTTps://newpaper24.com/vasant-narasimhan-ceo-novartis-technology-news-ettech-newpaper24/

hTTps://www.pressreader.com/india/the-economic-times/20180821/281887299156825